Skip to content
Home/Companies/Healthcare / Biotech/Delinia

Delinia

Healthcare / Biotech·UK·Exited 2017·Held 1yr
Entry
2016
Hold
1yr
Exit
2017

Who owns Delinia?

Delinia was owned by Sofinnova Partners through Sofinnova Capital VIII (2015 vintage) from 2016 to 2017, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital VIII · 2015 · Life Sciences VC

Key facts

HQUnited Kingdom
SectorHealthcare / Biotech
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2017

More from Sofinnova Capital VIII

Other portfolio companies in the same fund.

VectivBio
Exited 2023
BiotechSwitzerland· 2017
to
Breath Therapeutics
Exited 2019
BiotechGermany· 2016
to
Corvidia Therapeutics
Exited 2020
BiotechUS· 2016
to
ENYO Pharma
ENYO Pharma
Active
BiotechFrance· 2016
ReCor Medical
Exited 2018
MedTechUS· 2016
to
BiovelocITA
Active
BiotechItaly· 2015

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Delinia

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Delinia?

2 strategic and 118financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Delinia.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue